Biologics News
VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by CTI BioPharma Corp. as a specialty pharmacy provider for VONJO™ (pacritinib) for the treatment of intermediate or...
PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Agios Pharmaceuticals, Inc. as a specialty pharmacy provider for PYRUKYND® (mitapivat) for the treatment of hemolytic...
TARPEYO (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYO™ (budesonide) delayed release capsules...
BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson
CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi® (ropeginterferon alfa-2b-njft) for the...
Newly Approved LIVTENCITY (maribavir) Now Available at Biologics by McKesson
CARY, N.C., Dec. 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceuticals as a specialty pharmacy provider for LIVTENCITY™ (maribavir) indicated for the treatment of adults...
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITY™ (mobocertinib) for the...
WELIREG (belzutifan), FDA Approved, Available at Biologics by McKesson
CARY, N.C., August 20, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Merck & Co. as a specialty pharmacy provider for WELIREG™ (belzutifan) an inhibitor of hypoxia-inducible...
REZUROCK™ (belumosudil) Tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., JULY 30, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced that it has been selected by Kadmon (Nasdaq: KDMN) as a specialty pharmacy provider for REZUROCK™ (belumosudil) for the...
TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy...
LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with...